Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs ...
RAPT Therapeutics press release ( NASDAQ: RAPT ): Q2 GAAP EPS of -$0.62 beats by $0.12 . Revenue of $0.89M (+2.3% Y/Y) beats by $0.58M . As of June 30, 2022, the Company had cash, cash equivalents and marketable securities of $207.3 million, which includes net ...
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs ...
Gainers: MyMD Pharmaceuticals ( MYMD ) +23% . Clovis Oncology ( CLVS ) +22% . iRhythm Technologies ( IRTC ) +22% . Acer Therapeutics ( ACER ) +15% . Atreca ( BCEL ) +12% . Losers: RAPT Therapeutics ( RAPT ) -9% ...
RAPT Therapeutics (NASDAQ:RAPT) has announced a private placement financing of $50M. The PIPE financing was secured from the sale of pre-funded warrants, to purchase up to 4M shares of common stock at a price per pre-funded warrant of $12.4999, to Redmile Group. The transaction is expected to...
SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs i...
RAPT Therapeutics (NASDAQ:RAPT) said it began a phase 2b of oral drug RPT193 as a standalone therapy for patients with moderate-to-severe atopic dermatitis (AD), also known as eczema. The 16-week U.S.-based trial will compare three oral dose levels of RPT193 (50, 200 and 400 mg...
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs i...
RAPT Therapeutics press release (NASDAQ:RAPT): Q1 GAAP EPS of -$0.69 misses by $0.01. Revenue of $0.64M (-47.5% Y/Y) beats by $0.33M. For further details see: RAPT Therapeutics GAAP EPS of -$0.69 misses by $0.01, revenue of $0.64M beats by $0.33M
SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet ne...
News, Short Squeeze, Breakout and More Instantly...
RAPT Therapeutics Inc. Company Name:
RAPT Stock Symbol:
NYSE Market:
RAPT Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflamm...
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflamm...
2024-02-23 01:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...